NCT00023894已完成2 期
A Phase II Evaluation of Flavopiridol (NSC# 649890) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 107
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or persistent endometrial cancer.
详细描述
OBJECTIVES:
- Determine the antitumor activity of flavopiridol in patients with recurrent or persistent endometrial carcinoma.
- Determine the nature and degree of toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (107)
Loading locations...
相似试验
已完成
2 期
Flavopiridol in Treating Patients With Metastatic Malignant MelanomaMelanoma (Skin)NCT00005971NCIC Clinical Trials Group17
已完成
2 期
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue SarcomaSarcomaNCT00005974NCIC Clinical Trials Group18
已完成
2 期
Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell LymphomaLymphomaNCT00005074NCIC Clinical Trials Group33
已完成
2 期
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney CancerKidney CancerNCT00016939SWOG Cancer Research Network
已完成
1 期
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid TumorsMelanoma (Skin)Unspecified Adult Solid Tumor, Protocol SpecificBreast CancerProstate CancerNCT00003690Mayo Clinic48